Lung transplantation is the only therapeutic option for end-stage pulmonary failure. Nevertheless, the shortage of donor pool available for transplantation does not allow to satisfy the requests, thus the mortality on the waiting list remains high. One of the tools to overcome the donor pool shortage is the use of ex-vivo lung perfusion (EVLP) to preserve, evaluate and recondition selected lung grafts not otherwise suitable for transplantation. EVLP is nowadays a clinical reality and have several destinations of use. After a narrative review of the literature and looking at our experience we can assume that one of the chances to improve the outcome of lung transplantation and to overcome the donor pool shortage could be the tissue regeneration of the graft during EVLP and the immunomodulation of the recipient. Both these strategies are performed using mesenchymal stem cells (MSC). The results of the models of lung perfusion with MSC-based cell therapy open the way to a new innovative approach that further increases the potential for using of the lung perfusion platform.

Lung transplantation, ex-vivo reconditioning and regeneration: State of the art and perspectives / L. Rosso, A. Zanella, I. Righi, M. Barilani, L. Lazzari, E. Scotti, F. Gori, P. Mendogni. - In: JOURNAL OF THORACIC DISEASE. - ISSN 2072-1439. - 10:Suppl 20(2018 Jul 01), pp. S2423-S2430. [10.21037/jtd.2018.04.151]

Lung transplantation, ex-vivo reconditioning and regeneration: State of the art and perspectives

L. Rosso
Primo
;
A. Zanella
Secondo
;
M. Barilani;
2018-07-01

Abstract

Lung transplantation is the only therapeutic option for end-stage pulmonary failure. Nevertheless, the shortage of donor pool available for transplantation does not allow to satisfy the requests, thus the mortality on the waiting list remains high. One of the tools to overcome the donor pool shortage is the use of ex-vivo lung perfusion (EVLP) to preserve, evaluate and recondition selected lung grafts not otherwise suitable for transplantation. EVLP is nowadays a clinical reality and have several destinations of use. After a narrative review of the literature and looking at our experience we can assume that one of the chances to improve the outcome of lung transplantation and to overcome the donor pool shortage could be the tissue regeneration of the graft during EVLP and the immunomodulation of the recipient. Both these strategies are performed using mesenchymal stem cells (MSC). The results of the models of lung perfusion with MSC-based cell therapy open the way to a new innovative approach that further increases the potential for using of the lung perfusion platform.
Cell- and tissue-based therapy; Lung transplantation; Perfusion; Tissue and organ procurement; Pulmonary and Respiratory Medicine
Settore MED/21 - Chirurgia Toracica
Settore MED/41 - Anestesiologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
J Thorac Dis (Lung transplantation ex-vivo reconditioning ...).pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 434.81 kB
Formato Adobe PDF
434.81 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/606117
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact